Agoracom Blog

Empower Clinics $CBDT.ca Announces Closing of Acquisition of Sun Valley Clinics $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca $BUZZ.ca

Posted by AGORACOM-JC at 3:38 PM on Wednesday, May 1st, 2019
  • Completed the acquisition of Sun Valley Certification Clinics Holdings LLC
  • Operates a network of professional medical cannabis and pain management practices, with five clinics in Arizona, one clinic in Las Vegas, a tele-medicine platform serving California, and a fully developed franchise business model for the domestic cannabis industry
  • Will expand Empower’s multi-state operations, having a combined patient count of 165,000 patients, in Washington, Oregon, Illinois, Arizona, Nevada and California

VANCOUVER, May 1, 2019 - EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (“Empower” or the “Company“) is pleased to announce that, pursuant to the terms of a membership interest purchase agreement dated April 30, 2019, it has completed the acquisition of Sun Valley Certification Clinics Holdings LLC (“Sun Valley“) from Andrea Klein and Dustin Klein (together, the “Vendors“) and a minority shareholder, through its wholly-owned subsidiary, Empower Healthcare Assets Inc. (“Empower Health“), for cash and share consideration having an aggregate value of US$3,835,000 (CAD$5,160,376), effective as of April 30, 2019 (the “Transaction“). Sun Valley operates a network of professional medical cannabis and pain management practices, with five clinics in Arizona, one clinic in Las Vegas, a tele-medicine platform serving California, and a fully developed franchise business model for the domestic cannabis industry.

In connection with the Transaction, Empower also acquired the 30% minority membership interests held by Green Global Properties Inc. (“Green Global“), a subsidiary of Aura Health Inc. (CSE: BUZZ), in three partially-owned subsidiaries of Sun Valley, operating clinics in Mesa and Phoenix, Arizona, and Las Vegas, Nevada, such that Empower now indirectly owns all of the membership interests in each of such subsidiaries (the “GG Acquisition“).

Over the past five years, Dustin and Andrea have built one of the most reputable and organized clinic networks in Arizona, developing a patient list of more than 45,000 unique patients, and have performed over 61,000 certifications to date. Sun Valley supports its patients with a dynamic dedicated team consisting of 52 staff, including 30 physicians.

“The acquisition of the Sun Valley clinic group has fundamentally changed the direction and growth prospects for Empower,” said Steven McAuley, Empower’s Chairman & CEO. “We have repositioned Empower as a vertically integrated global health and wellness company, helping consumers access products and specialized medical care for serious qualifying conditions. Having Dustin and Andrea Klein join me in leadership to rapidly expand Empower’s clinic and distribution network across the United States is a major step toward our ambitious objectives.”

“This acquisition is a testament to the hard work and dedication our team has provided to our community for the past five years and I look forward to being a valuable resource to the Company and on the board of directors,” said Dustin Klein, Sun Valley Co-founder.

Andrea Klein, Sun Valley Co-founder, stated, “I am delighted with our acquisition by Empower Clinics! It is the evolution of our dream, to positively affect the lives of patients across the country, and to become an adaptive and strategic organization that can harness the phenomenal and exciting growth of the cannabis industry. Steve’s vision for Empower is inspiring, and I am eager to bring our team together with his vision and grow into a dominating national brand that leads the way in patient care, employee satisfaction, and potential shareholder profitability!”

The Transaction is expected to create one of the largest clinic groups in the medical cannabis sector in the United States, which, together with Empower’s existing medical cannabis clinics, will expand Empower’s multi-state operations, having a combined patient count of 165,000 patients, in Washington, Oregon, Illinois, Arizona, Nevada and California, and the potential to rapidly expand the clinic network via the Sun Valley franchise program.

TRANSACTION HIGHLIGHTS

  • Improved Capital Markets Profile Empower is diversifying its business model to become a vertically integrated operator in the global cannabis sector with a focus on patient care, CBD product distribution, research & development and CBD product extraction. The Company believes this will appeal to a broader base of shareholders and investors and provide greater access to capital and improved trading liquidity.

  • Increased Patient Access With a rapidly expanding company-owned clinic network and significant expansion opportunity through the Sun Valley franchise model, Empower anticipates it will grow its total patient list substantially in the years ahead. This is expected to provide greater opportunity for treatment analysis using artificial intelligence (AI), validating the Company as a leader in understanding the efficacy of cannabis-related therapies.

  • Focus on CBD Product Sales Empower’s patient base and customers are expected to benefit from access to high margin derivative products, including CBD lotion, tinctures, spectrum oils, capsules, lozenges, patches, e-drinks, topical lotions, gel caps, hemp extract drops and pet elixir hemp extract drops. Patients and customers will be able to access Empower’s customer service, home delivery and e-commerce platform.

  • Market Leading Technology Empower utilizes a market-leading patient electronic management and POS system that is HIPAA compliant and provides deep insight to patient care. The Company supports remote patients using its tele-medicine portal, enabling patients who do not live near one of its clinic locations, or are disabled or unable to come to a location, to still benefit from a doctor consultation.

  • The Sun Valley Clinic Locations

4218 W Dunlap Ave, Phoenix, AZ
12801 W Bell Rd #145, Surprise, AZ
4015 E Bell Rd #130, Phoenix, AZ
2011 E University Dr, Mesa, AZ
7074 E Speedway Blvd, Tucson, AZ
2550 S Rainbow Blvd, Las Vegas, NV

In connection with the closing of the Transaction (the “Closing“), Empower: (i) paid the Vendors an aggregate cash payment of US$775,000 (CAD$1,042,840), of which US$150,000 (CAD$201,840) is being heldback by Empower, half of which is to be released six months from the date of Closing and the other half of which is to be release twelve months from the date of Closing and (ii) issued the Vendors an aggregate of 22,058,823 common shares in the capital of the Company (each a “Share“) at a deemed price of US$0.136 (CAD$0.183) per Share, representing the average daily closing price of the Shares on the Canadian Securities Exchange for the 10-day trading period ended April 26, 2019. 14,705,882 of the Shares will be held in escrow by Odyssey Trust Company pursuant to an escrow agreement dated April 30, 2019, and will vest in quarterly installments over 36 months from the date of the Closing. The Company also paid US$12,318 (CAD$16,575) and issued 350,602 Shares to a minority shareholder of one of the Sun Valley subsidiaries in order to acquire her minority interest therein.

Each of the Vendors have also entered into employment agreements with an affiliate of the Company pursuant to which Dustin Klein will serve as the Vice President of Business Development, and Andrea Klein will serve as the Vice President of Operations. In these roles, they will continue to provide their extensive industry knowledge and expertise to Sun Valley and the Company. In addition, Dustin Klein has been appointed as a director of the Company, effective as of the Closing.

In consideration for the GG Acquisition, Empower Health issued Green Global a promissory note in the principal amount of US$125,000, which bears interest at the rate of 4.0% per annum and has a maturity date of July 31, 2019.

None of the Shares to be issued in connection with the Transaction will be registered under the United States Securities Act of 1933, as amended (the “1933 Act“), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons” (as such term is defined in Regulation S under the 1933 Act), absent registration or an applicable exemption from such registration requirements.

ABOUT EMPOWER

Empower is a leading multi-state operator of a network of physician-staffed clinics focused on helping patients improve and protect their health through innovative physician recommended treatment options. It is expected that Empower’s proprietary product line “Sollievo” will offer patients a variety of delivery methods of doctor recommended cannabidiol (CBD) based products in its clinics, online and at major retailers. With over 165,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine, and an expanded product development strategy, Empower is undertaking new growth initiatives to be positioned as a vertically integrated, diverse, market-leading service provider for complex patient requirements in 2019 and beyond.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the direction and growth prospects of the Company, the expansion of the company’s clinic and distribution network, the expected effect of the Vendors in their new roles with the Company, the effect on the lives of patients, the growth into a national brand, the effect of the Transaction, the diversification of the Company’s business model, the potential appeal to shareholders, the growth of the Company’s patient list and the effect thereof, the expected benefits for the company’s patient base and customers, the release of the cash consideration, the release of Shares being held in escrow in connection with the Transaction and statements regarding the Company’s proprietary product line “Sollievo”. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including that the Company may not be able to expand, that the Transaction may not have the expected results, and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2019/01/c3033.html

Investors: Steve Low, Boom Capital Markets, 647-620-5101; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-6274; Investors: Steven McAuley, CEO, [email protected], 604-789-2146Copyright CNW Group 2019

Esports Entertainment Group $GMBL – #Esports organization #Fnatic raises $19 million for big expansion $TECHF $ATVI $TTWO $GAME $EPY.ca $FDM.ca $TNA.ca

Posted by AGORACOM-JC at 2:41 PM on Wednesday, May 1st, 2019
SPONSOR: Esports Entertainment $GMBL Esports audience is 350M, growing to 590M, Esports wagering is projected at $23 BILLION by 2020. The company has launched VIE.gg esports betting platform and has accelerated affiliate marketing agreements with 190 Esports teams. Click here for more information
GMBL: OTCQB

———————–

Esports organization Fnatic raises $19 million for big expansion

By Hilary Russ

  • Fnatic, the London-based global esports team owner, has raised $19 million in new funding and restructured its leadership as it plans a major expansion
  • Company plans to further expand in Asia and North America and grow from a headcount of 150 people now to 1,000 in the next five years

NEW YORK (Reuters) – Fnatic, the London-based global esports team owner, has raised $19 million in new funding and restructured its leadership as it plans a major expansion, the company said on Wednesday.

The company plans to further expand in Asia and North America and grow from a headcount of 150 people now to 1,000 in the next five years, founder Sam Mathews told Reuters.

It will use the investments to strengthen its teams with new nutrition and psychology programs, and physical training coaches for players – lessons Mathews said he took from the British cycling team.

It also plans to launch a new line of audio equipment, particularly headsets.

Esports – professional video game competitions that are watched by throngs of fans live and online – have been around for over a decade but have seen audiences and sponsorships grow significantly in the last couple of years.

It has also attracted big brands looking to advertise to young fans and sponsor teams and stars, including Walt Disney Co, Hershey Co and Toyota Motor Corp.

Global esports revenue will hit $1.1 billion in 2019, up 27 percent since last year amid an increase in advertising, sponsorship and media rights to competitive video gaming, according to the gaming analytics firm Newzoo.

Esports will be one of “the most valuable sports in the next 10 years,” Mathews said.

Fnatic, one of the oldest and largest teams in global esports, has won major titles in several games, including League of Legends and Counter-Strike. It currently fields teams in 10 different games and also sells its own line of gear and clothing.

Mathews started Fnatic in 2004 with $40,000 in family funds and help from his mother, Anne.

The company previously raised about $7.5 million in financing, including from Raptor Group Holdings, founded by investment manager Jim Pallotta, co-owner of the Boston Celtics professional basketball team.

In 2015, Fnatic acquired the gaming equipment maker FUNC in order to produce its own gear, including keyboards and mice, which are now sold in over 400 Best Buy stores in the United States.

The new investment round was led by tech entrepreneur Lev Leviev of LVL1 Group, who also joins the board, Fnatic said in a statement.

The investment round also includes British venture capital firm Beringea, Hong Kong private equity firm BlackPine, London-based investment firm Unbound and venture capitalist Joi Ito, who is also director of the MIT Media Lab.

Under the new leadership structure, Mathews will be chief executive. Nick Fry, former CEO of the Mercedes AMG Formula One motor racing team, returns to Fnatic as chairman, while Glen Calvert, founder of advertising firm Affectv, was appointed chief operating officer.

(This story corrects paragraph 13 to show tech investor Lev Leviev is the lead investor, not the Israeli diamond mogul of the same name)

(Reporting by Hilary Russ; Editing by Bill Berkrot and Jon Boyle)

Source: https://www.thetelegram.com/business/esports-organization-fnatic-raises-19-million-for-big-expansion-307335/

CLIENT FEATURE: CardioComm Solutions $EKG.ca – Connecting Your Heart To The Cloud $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 11:54 AM on Wednesday, May 1st, 2019

Global Leaders in Mobile  ECG Connectivity

  • 20 years of medical credibility licensing technologies to hospitals, physicians, remote patient monitoring  platforms, research groups and commercial call centers
  • Sold into > 20 countries, with the largest customer base located in the US
  • Class II medical device clearances and device agnostic for collecting, viewing, recording, analyzing and  storing of ECGs for management of patient and consumer health
  • ECG solutions for both consumer (OTC) and medical (Rx) markets
  • Owns all IP and source code
  • Market expert contributor for reports in m‐health, mobile cardiac monitoring and new advances in  consumer health and wellness monitoring

Company Accolades

FULL DISCLOSURE: CardioComm Solutions Inc. is an advertising client of AGORA Internet Relations Corp.

BetterU Education Corp. $BTRU.ca – As universities go online, education landscape set to change; growth to match US, Europe #Edtech $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 10:20 AM on Wednesday, May 1st, 2019
SPONSOR:  Betteru Education Corp. Connecting global leading educators to the mass population of India. BetterU Education has ability to reach 100 MILLION potential learners each week. Click here for more information.
BTRU: TSX-V

————————

As universities go online, education landscape set to change; growth to match US, Europe

Total enrolment in online education will grow at 33.6 per cent CAGR and cross 2.12 crore by 2022.

By: Eram Tafsir

  • With the universities going online in India, the education scenario is set to change tremendously, making the country’s growth rate of enrollment at par with that of the United States of America and Europe, according to a report.
  • Total enrollment in online education will grow at 33.6 per cent CAGR and cross 2.12 crore by 2022.

UGC regulations have allowed universities to offer online programs, which were not legal in India till now. This, combined with the continued government efforts would help make education available to many who are willing to pursue it but lacked time and access.

The enrollment in Online Degree or Diploma Programs will experience 14.5 per cent CAGR growth and will reach 63.63 lakh by 2022, according to a recent report titled ‘Trends and opportunities in the online learning market’ released by Schoolguru Eduserve (a TeamLease group company). This growth in enrolment will become comparable to that of the United States of America and Europe where it is 16 per cent and 12 per cent respectively, the report added.

Not just the higher online education, but the whole gamut of online education ecosystem including formal degree re-skilling programs, will see an exponential growth, the report added.

Total enrollment in online education will grow at 33.6 per cent CAGR and cross 2.12 crore by 2022. The online re-skilling and certification market (for the repair and upgrade) will reach Rs 3,333 crore by 2022.

Noting that there has been a rapid evolution in the field online education over the last five years, the report expects the industry to soon enter the era of Virtual and Augmented Reality at the learner-end and AI and machine learning at the back-end.

However, the report noted several challenges faced by the online education sector such as language familiarity, high fees, Lengthy duration of the course and enrolment procedure, unavailability of qualified online instructors, inadequate student-faculty interactions.

According to the report, some of the hindrances that the online education sector is facing are unavailability of qualified online instructors, inadequate student-faculty interactions, duration of the course, lengthy enrollment procedure and high fees.

Online education is not only a growing industry, but is an effective model to address the challenges of cost, equity, and employability in our education system and help the industry to prepare, repair and upgrade of its workforce, CEO and Founder, Schoolguru Eduserve Pvt. Ltd Shantanu Rooj said. Online learning has the potential to increase the gross-enrollment ratio (GER) rates from the current 25 per cent to 30 per cent and if blended with on-job learning, can help improve the employability of our youth in India dramatically, he added.

Source: https://www.financialexpress.com/economy/as-universities-go-online-education-landscape-set-to-change-growth-to-match-us-europe/1564417/

Monarch Gold $MQR.ca Produces 1,328 Ounces of Gold and Generates $5.2 Million in Revenue in its Third Quarter $GDX.ca $ECR.ca $MZZ.ca $QMX.ca $IMG.ca $IAG $MUX

Posted by AGORACOM-JC at 9:20 AM on Wednesday, May 1st, 2019


  • Custom milling operations at the Camflo mill contribute strongly to revenues
  • Production at the Beaufor mine declines due to a lower production rate
  • The Wasamac gold project continues to draw considerable interest from potential partner
  • The Corporation completed a positive feasibility study on its Wasamac deposit during the second quarter (see feasibility study), with the following results:
    • Forecast average production: 142,000 ounces of gold over 11 years
    • Pre-tax NPV: $522 million
    • Pre-tax IRR: 23.6%
    • Cash cost: US $550 per ounce

MONTREAL, May 1, 2019 /CNW/ – MONARCH GOLD CORPORATION (“Monarch” or the “Corporation”) (TSX: MQR) (OTCMKTS: MRQRF) (FRANKFURT: MR7) is pleased to report its production and corporate highlights for the third quarter ended March 31, 2019. Amounts are in Canadian dollars unless otherwise indicated.

Production highlights

  • Monarch produced 1,328 ounces of gold in the third quarter, down 70% from the second quarter and 73% from 4,932 ounces produced last year. The decrease was attributable to a cut in the production rate and number of employees at the Beaufor mine in January 2019.

  • The Corporation recorded revenues of $5.2 million in the third quarter from the sale of 1,427 ounces of gold at an average price of $1,737 per ounce (US $1,307) plus custom milling revenue, which was down 6.2% from the second quarter due to a planned shutdown at the Camflo mill for maintenance work, but  up 35.5% year over year.

“Our custom milling operations at the Camflo mill continue to perform well despite the lower tonnage from the Beaufor mine,” said Jean-Marc Lacoste, President and Chief Executive Officer of Monarch. “The Beaufor mine is currently operating at a reduced average rate of 7,000 tonnes per month with about 50 employees, and we are reassessing the mine’s operations on a monthly basis.”

“Our promising projects are unquestionably the Wasamac, Croinor Gold and McKenzie Break advanced gold projects. The Wasamac project continues to draw considerable interest from the mining and financial community, as evidenced by the increased virtual room traffic. We have also had preliminary discussions with a number of parties and will continue to work with them in the coming weeks. Meanwhile, Croinor Gold and McKenzie Break generated excellent drill results in 2018, which increased the gold potential of these projects.”

Production statistics

Three months ended March 31, 2019 Three months ended March 31, 2018 Nine months ended March 31, 2019 Nine months ended March 31, 2018
Beaufor mine
Ore processed (tonnes) 13,110 32,866 68,564 67,871
Gold recovery (%) 97.78 98.91 98.15 98.78
Ounces produced 1,328 4,932 9,653 10,376
Ounces sold 1,427 4,823 9,868 10,267

Corporate highlights

  • On February 4, 2019, the Corporation reported the last assay results from the 2018 diamond drill program at its wholly owned Croinor Gold project, which notably returned 17.26 g/t Au over 1.95 metres, including 50.10 g/t Au over 0.6 metres (see press release).

  • On February 7, 2019, the Corporation announced the appointment of Mathieu Séguin as Vice President, Corporate Development (see press release).

  • On February 28, 2019, the Corporation reported the first assay results from the 2018 diamond drilling program at its wholly owned McKenzie Break gold project, which notably returned 61.20 g/t Au over 2.6 metres, including 265.00 g/t Au over 0.6 metres (see press release).

  • On March 13, 2019, the Corporation reported the second set of assay results from the 2018 diamond drilling program at its wholly owned McKenzie Break gold project, which notably returned 24.40 g/t Au over 2.0 metres, including 93.80 g/t Au over 0.5 metres (see press release).

  • On March 20, 2019, the Corporation reported the third and last set of assay results from the 2018 diamond drilling program at its wholly owned McKenzie Break gold project, which notably returned 12.60 g/t Au over 1.35 metres, including 55.90 g/t Au over 0.3 metres (see press release).

  • On March 29, 2019, the Corporation reported that it had sold its Pandora royalty to Agnico Eagle Mines Limited, thus reducing its payments for the McKenzie Break and Swanson properties by $800,000 (see press release).

  • On April 26, 2019, the Corporation announced the closing of a $2,000,000 private placement (see press release).

The Corporation has also received the assay results for the 1,750-metre drilling program carried out in February 2019 on the Croinor Gold property. The program included seven exploration holes drilled more than one kilometre away from the Croinor Gold deposit. While the holes did not return any significant intersections, they did yield important geological data. The Corporation still believes that Croinor Gold holds excellent exploration potential along strike and at depth, as these holes targeted only a small portion of the 151 km2 property. In fact, the Corporation plans to continue additional exploration work on Croinor Gold to locate additional drilling targets. On the MacKenzie Break property, the Corporation is currently planning its next drilling program on high potential targets.

Finally, the recommissioning of the Beacon plant has been delayed, mainly because the Corporation has not yet received the operating permits or obtained the financing needed to put the Croinor Gold deposit back into production.

The technical and scientific content of this press release has been reviewed and approved by Marc-André Lavergne, P.Eng., the Corporation’s qualified person under National Instrument 43‑101.

ABOUT MONARCH GOLD CORPORATION

Monarch Gold Corporation (TSX: MQR) is an emerging gold mining company focused on pursuing growth through its large portfolio of high-quality projects in the Abitibi mining camp in Quebec, Canada. The Corporation currently owns close to 300 km² of gold properties (see map), including the Wasamac deposit (measured and indicated resource of 2.6 million ounces of gold), the Beaufor Mine, the Croinor Gold (see video), McKenzie Break and Swanson advanced projects and the Camflo and Beacon mills, as well as other promising exploration projects. It also offers custom milling services out of its 1,600 tonne-per-day Camflo mill.

Forward-Looking Statements
The forward-looking statements in this press release involve known and unknown risks, uncertainties and other factors that may cause Monarch’s actual results, performance and achievements to be materially different from the results, performance or achievements expressed or implied therein. Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX accepts responsibility for the adequacy or accuracy of this press release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/monarch-gold-produces-1-328-ounces-of-gold-and-generates-5-2-million-in-revenue-in-its-third-quarter-300841757.html

SOURCE Monarch Gold Corporation

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2019/01/c5907.html

Jean-Marc Lacoste, 1-888-994-4465, President and Chief Executive Officer, [email protected]; Mathieu Séguin, 1-888-994-4465, Vice President, Corporate Development, [email protected]; Elisabeth Tremblay, 1-888-994-4465, Senior Geologist – Communications Specialist, [email protected], www.monarquesgold.comCopyright CNW Group 2019

PyroGenesis $PYR.ca Announces 2018 Results: Revenues of $5.03MM; Gross Margin of 22%; Current Backlog $7.7MM $LMT $RTN $NOC $UTX $HPQ.ca $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 8:29 AM on Wednesday, May 1st, 2019
  • Revenues of $5,030,116
  • Gross margin of 22.1%
  • Backlog of signed contracts of $7.7MM

MONTREAL, April 30, 2019 – PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, today announced its financial and operational results for the fourth quarter and the fiscal year ended December 31, 2018.

“2018 was significantly affected by management’s decision to pursue strategic partnerships at the expense of revenues. However, as a result, we have press released imminent contracts in excess of $32MM with associated future revenues in excess of that,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “Therefore if 2018 was the year in which the Company successfully positioned itself with unique and strategic partnerships, geared to effectively accelerate commercialization, then 2019 is the year that bears the fruit of that strategy. We strongly recommend that these financials be viewed in this context.”

2018 was a year in which PyroGenesis posted:

  • Revenues of $5,030,116, a decrease of 30% from $7,192,861 year over year;
  • Gross margin of 22.1% a decrease of 21.4% year over year;
  • R&D costs of $892K, an increase of 208% from $290K year over year, the increase is related to torch development and plasma atomization related expenses;
  • Leasehold improvements of $821K were spent to build a clean room for Plasma atomization system;
  • A Modified EBITDA loss of $5.3MM compared to a Modified EBITDA loss of $1.45MM year over year;
  • Backlog of signed contracts as of the date of this writing is $7.7MM;
  • Cash on hand on December 31, 2018 was $645K (December 31, 2017: $623K).

Outlook

2018 was a year in which PyroGenesis successfully positioned each of its commercial business lines for rapid growth by strategically partnering with multi-billion-dollar entities who have identified PyroGenesis’ offerings to be unique, in demand, and of such a commercial nature as to warrant such unique relationships.

By the end of 2018 PyroGenesis could boast of a unique relationship with a multi-billion-dollar entity in each of its three commercial offerings:

1) The US Navy within the Military/Environmental sector;
2) A Japanese trading house within the DROSRITETM (tolling) offering;
3) Aubert & Duval within the Additive Manufacturing/3D printing (“AM”) offering.

Most companies would be thankful for one such relationship, but PyroGenesis has successfully developed three.

It became readily apparent to management that partnering with the right entity could significantly accelerate commercialization in each of its new business lines. This however, would come with a cost in 2018. In order to succeed, PyroGenesis would have to dedicate significant resources to demonstrating the value proposition, and capabilities, to these entities. This meant that assets which should have been dedicated to sales now had to be deployed to developing these relationships. This not only impacted revenues, but it also increased costs of non-paying projects.

If 2018 was the year in which the Company successfully positioned itself with unique and strategic partnerships, geared to effectively accelerate commercialization, then 2019 is the year that bears the fruit of that strategy.

To date, PyroGenesis has announced that it should be awarded a two-ship build for its PAWDS unit shortly, for approximately $12.5MM. Add to this the recently announced potential contract with 1st year revenues of $20MM ($30-$50MM in subsequent years revenues) and the impact of this strategy is apparent: over $30 MM in revenues over the next 18 months. Approximately 6x 2018 revenues.

With these two contracts in hand alone, 2019 will be a profitable year.

2019 should also be the year in which the Company takes steps, outside of the ordinary course of business, to unlock additional value for investors.

One such step that has been announced is the spin-off of the Company’s additive manufacturing capabilities.  Management has decided that, given all it knows, that a spin off at this time should unlock additional value for investors as it would:

(i)Attract an investor base best suited to the Company’s AM value proposition, particular business operations, and financial characteristics. There are large pools of money interested in investing in the AM space, but have no desire to have their funds comingled with unrelated business lines. A spin-off would assure them that such funds would be used for AM alone.
(ii)Maximize shareholder value by placing the spin-off in a better position to generate revenues and develop strategic relationships than had it remained part of the PyroGenesis stable of technologies
(iii) Simplify the offering making it easier for analysts to understand and value it properly. As it stands now PyroGenesis Additive is part of PyroGenesis Canada Inc’s offerings which include Drosrite™, US Military, and Purevap™, just to name a few, and as such makes it complicated to analyze.  Last but not least, a spin-off creates a well understood entity with which interested parties could joint venture or acquire.

Another step, which is likewise outside the ordinary course of business, and is geared to unlocking shareholder value, is the previously announced up-listing of the Company’s stock to a more senior exchange other than the one the Company is currently on.

There are other steps, outside the ordinary course of business, that the Company is considering to increase shareholder value and these will each be announced in due course.

2019 is positioned to be the first year, of many, that will bear the fruit of strategic decisions made in the recent past.

Financial Summary

Revenue

PyroGenesis recorded revenue of $5,030,116 in the year of 2018, representing a decrease of 30% compared with $7,192,861 recorded in the year of 2017.

Revenues recorded in fiscal 2018 were generated primarily from:

(i)PUREVAP™ related sales of $1,781,009 (2017 – $2,330,691);
(ii)DROSRITE™ related sales of $1,237,740 (2017 – $98,391));
(iii)Support services related to PAWDS-Marine Systems supplied to the US Navy $1,451,998 (2017 – $4,337,681).
(iv)Other sales and services $559,369 (2017 – $426,098)

Cost of Sales and Services and Gross Margins

Cost of sales and services before amortization of intangible assets was $3,860,493 in 2018, representing a decrease of 5% compared with $4,065,894 in 2017.

In 2018, employee compensation, direct materials and manufacturing overhead decreased to $3,590,381 (2017 – $4,338,252) while subcontracting increased to $364,463 (2017- $98,256). The gross margin for 2018 was $1,109,297 or 22.1% of revenue compared to a gross margin of $3,126,967 or 43.5% of revenue for 2017.

The gross margin for 2018, was $1,109,297, or 22.1% of revenue. This compares with a gross margin of $3,126,961 (43.5% of revenue) for 2017.

As a result of the type of contracts being executed, the nature of the project activity had a significant impact on the gross margin and the overall level of cost of sales and services reported in a period, as well as the composition of the cost of sales and services, as the mix between labour, materials and subcontracts may be significantly different. The cost of sales and services for 2018 and 2017 are in line with management’s expectations.

The amortization of intangible assets of $60,326 in 2018 and $Nil for 2017 relates to patents and deferred development costs. Of note, these expenses are non-cash items and will be amortized over the duration of the patent lives.

Selling, General and Administrative Expenses

Included within Selling, General and Administrative expenses (“SG&A”) are costs associated with corporate administration, business development, project proposals, operations administration, investor relations and employee training.

SG&A expenses for 2018 excluding the costs associated with share-based compensation (a non-cash item in which options vest principally over a four-year period), were $5,864,528, representing an increase of 33% compared with $4,394,837 reported for 2017. 

The increase in SG&A expenses in 2018 over the same period in 2017 is mainly attributable to the net effect of:

  • an increase of 32% in employee compensation due primarily to additional headcount,
  • an increase of 55% for professional fees, primarily due to an increase in consulting fees, legal fees and patent expenses,
  • an increase of 6% in office and general expenses, due to an increase in telephone & internet expenses and stationary & office expenses,
  • travel costs increased by 21%, due to an increase in travel abroad,
  • depreciation on property and equipment increased by 90% due to higher amounts of property and equipment being depreciated. In 2018, depreciation was taken on the Plasma atomization system (previously asset under development). In 2017 there was no depreciation on asset under development,
  • government grants increased by 100% due to a government grant contribution for a maximum amount of $350,000 for the period 2018-2020,
  • other expenses increased by 35%, primarily due to an increase in marketing expenses, and in sub-contracting expenses.

Separately, share based payments decreased by 11% in 2018 over the same period in 2017 as a result of the vesting structure of the stock option plan including the stock options granted in 2018.

Research and Development (“R&D”) Costs

The Company incurred $892,045 of R&D costs, net of government grants, on internal projects in 2018, an increase of 208% as compared with $289,851 in 2017. The increase in 2018 is related to torch development and plasma atomization related expenses.

In addition to internally funded R&D projects, the Company also incurred R&D expenditures during the execution of client funded projects. These expenses are eligible for Scientific Research and Experimental Development (“SR&ED”) tax credits. SR&ED tax credits on client funded projects are applied against cost of sales and services.

Inventory       

The Company’s inventory as at December 31, 2018 was $382,832 which includes powders, raw material and spare parts compared with $123,735 for the same period in 2017.

Net Comprehensive Loss

The net comprehensive loss for 2018 of $7,845,800 compared to a loss of $6,174,303, in 2017, represents an increase of 27% year-over-year.

The increase of $1,671,497 in net comprehensive loss in 2018 is primarily attributable to the factors described above, which have been summarized as follows:

(i)a decrease in product and service-related revenue of $2,162,745 arising in 2018,
(ii)a decrease in cost of sales and services totaling $145,075, primarily due to an increase in an increase in subcontracting, a decrease in investment tax credits, and an increase in amortization of intangible assets.
(iii)an increase in SG&A expenses of $1,383,927 arising in 2018 primarily due to an increase in employee compensation, professional fees, travel, depreciation on property & equipment, and other expenses,
(iv)an increase in R&D expenses of $602,194 primarily due to the increase in employee compensation, subcontracting, materials & equipment and other expenses,
(v)a decrease due to the settlement of the claim related to the IP debt balance of $3,215,643, an increase in net finance costs of $883,349 in 2018.

EBITDA

The EBITDA loss in 2018 was $6,864,461 compared with an EBITDA loss of $5,558,640 for 2017, representing an increase of 23% year-over-year. The increase in the EBITDA loss in 2018 compared with 2017 is due to the increase in comprehensive loss of $1,671,497, offset by an increase depreciation on property and equipment of $100,685, an increase amortization of intangible assets of $60,326 and an increase in finance charges of $204,665.

Adjusted EBITDA loss in 2018 was $6,191,212 compared with an Adjusted EBITDA loss of $1,583,985 for 2017. The increase of $4,607,227 in the Adjusted EBITDA loss in 2018 is attributable to an increase in EBITDA loss of $1,305,821, offset by a decrease of $85,764 in share-based payments and a decrease in the settlement of a claim related the long-term debt of $3,215,643.

The Modified EBITDA loss in 2018 was $5,271,749 compared with a Modified EBITDA loss of $1,445,785 for 2017, representing an increase of 265%. The increase in the Modified EBITDA loss in 2018 is attributable to the increase as mentioned above in the Adjusted EBITDA of $4,607,227 and a decrease in change of fair value of investments of $781,263.

Liquidity

The Company has incurred, in the last several years, operating losses and negative cash flows from operations, resulting in an accumulated deficit of $51,066,540 and a negative working capital of $4,101,429 as at December 31, 2018 (December 31, 2017 – $43,200,708 and $9,527,105 respectively). Furthermore, as at December 31, 2018, the Company’s current liabilities and expected level of expenses for the next twelve months exceed cash on hand of $644,981 (December 31, 2017 – $622,846). The Company has relied upon external financings to fund its operations in the past, primarily through the issuance of equity, debt, and convertible debentures, as well as from investment tax credits.

Separately, PyroGenesis is pleased to announce that Mr. Lelio Lato has joined the Company as V.P. Finance. As a CPA and CFA with over 20 years of experience, he has worked in various senior management roles across small cap technology companies with extensive capital markets knowledge.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, having been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.
Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

CLIENT FEATURE: $GRAT.ca Gratomic Submits Mining License: Able to Start Aukam Graphite Mine at Full Capacity $DNI.ca $LLG.ca $ECO.ca

Posted by AGORACOM at 12:45 PM on Monday, April 29th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564608/hub/Gratomic_large_new.jpg
Vertically integrated graphite to graphene advanced materials development company
  • Gratomic submitted its application for Mining License 215 (M L215).
  • The License area falls within the proximity of the Aukam Processing Plant and the Graphite bearing shear zone for a total of 5002 hectares
  • The mining license was the last step required for the company to go into full production.
  • The license submission is timed strategically with the construction of Gratomic’s onsite processing plant located at the Aukam Graphite Mine in Namibia and in conjunction with the recently announced long-term Graphene supply agreement with Vittoria Tires and Gratomic’s partner Perpetuus Advanced Materials
http://blog.agoracom.com/wp-content/uploads/2019/01/image-600x290.png

About Gratomic Inc.

Gratomic is an advanced material company focused on mine to market commercialization of graphite products, most notably high-value graphene-based components for a range of mass market products.

Gratomic Hub on Agoracom

PyroGenesis Announces Potential Contract; Over $20M First Year Revenues Plus Significant Subsequent Years Revenues $LMT $RTN $NOC $UTX $HPQ.ca $DDD.ca $SSYS $PRLB

Posted by AGORACOM at 9:16 AM on Monday, April 29th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564601/hub/PYR_header_1.png

MONTREAL, April 29, 2019 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, today announced that a potential contract (“Contract”) of over $20M in first year revenues, together with significant subsequent years revenues, is imminent.

Mr. P. Peter Pascali, President and CEO of PyroGenesis, provides additional information in the following Q&A format.

Q. How significant is this potential Contract?

A. If awarded, as we anticipate, this Contract would be the single largest Contract in the Company’s history, representing over 3x last year’s revenues, and addresses the need of a very significant entity. Obviously, this Contract would also make PyroGenesis profitable.

Q. Do you have the infrastructure in place to perform under this Contract and will you need to hire additional personal to complete?

A. We have both the infrastructure and personnel in place to complete the project. We do not anticipate the need for additional capex or hiring more than one additional person. As a result, we anticipate very high margins with this Contract.

Q. Can you give us a sense of the economics, timeframe and details of the subsequent year revenues?

A. Most certainly.

First year revenues of $20M, together with subsequent year revenues, all meet our minimum targeted gross margins.

The net present value of all subsequent year’s revenues (using a 5% discount rate) is between $30-50M, giving the Contract a total value of between $50-70M.

Q. Why did you say “imminent”, and what are the next steps?

A. We said imminent because we expect this to be formally recognized shortly. Once this formal recognition has taken place, there will be a contractual arrangement after which a formal signing will kick off the Contract. This contractual arrangement will be quite detailed as it spans several years.

Q. What product line is this Contract for?

A. As much as I would like to, I cannot disclose, at this time, which business line it is in, or even where it is geographically. What I can disclose is that it is not related to our Military business line, and that it fits very well with our announcements over the past six months.

Q. How confident are you that this will materialize in the near term? 

A. There is always a risk, but we are of the opinion that all major hurdles have been dealt with, and the path is now clear to contract. As a result, we felt this was material news and we have an obligation to our shareholders to disclose at this time even before the formal contract is awarded.

Q. How does this impact the long-term prospects for the Company?

A. As disclosed, this will be a very significant Contract for the Company. This is in addition to the approximately $12M in revenues that will be generated from the two-build order for Plasma Waste Destruction Systems for the US Navy, we previously announced, which translates into combined revenues well in excess of $30M over the next 12-18 months.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

Tetra Bio-Pharma $TBP.ca and Altus Formulation Sign Joint Venture Agreement for Cannabinoid Drug Product Development $AERO $CBDS $CGRW $APH.ca

Posted by AGORACOM at 8:33 AM on Monday, April 29th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564502/hub/Logo-TetraBioPharma-RGB-web.png

OTTAWA, April 29, 2019 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Altus Formulation Inc. (“Altus”) today announced the signing of a Joint Venture Agreement under which the two companies will work together to develop a series of cannabinoid-receptor targeted therapeutics addressing multiple areas of high unmet need.

The Joint-Venture will synergize the capabilities of the two companies:

  • Products:  The companies have identified product candidates in the fields of pain, oncology and ophthalmology, addressing a total market size of over $10BN. (Source: MedTrack™)
     
  • New Routes of Administration: Altus’ SmartCelle™ insoluble drug delivery platform enables intravenous, topical, intra-nasal and oral delivery. Smartcelle’s™ proven ability to enhance the solubility of cannabinoids permits increased oral absorption and enables low volume parenteral and transmucosal delivery.  Intellitab™ and Flexitab™ technologies will deliver Safer to Use™ products to patients.
     
  • New Intellectual Property:  Altus’ distinct drug delivery technologies provide Tetra with significant strategic advantages over the competition and will enable Tetra to significantly improve some of the current products under development. In addition to SmartCelle™ these include Intellitab™ abuse deterrent technology platform and, Flexitab™ breakable sustained release tablet technology for enhanced dosing flexibility.  All platforms are protected by patents enforced globally. 

  • Commercial Development, Manufacturing and Supply.  Combining Altus and Tetra capabilities ensures these essential parts of the value chain are addressed early and efficiently.

Dr. Guy Chamberland, CEO and CSO of Tetra stated, “We are extremely excited about finalizing this agreement which will enable us to improve existing products and will allow us to exploit a  number of different delivery mechanisms including Intra-Nasal, Intravenous and Oral Sustained Release Tablets.   Furthermore, Altus’ technology will play a key role in strengthening Tetra’s Intellectual Property for its product portfolio.  This newly created joint-venture will also serve to benefit our patients, their care providers and help us in our quest to replace the use of opioids.”

Damon Smith President and CEO of Altus Formulations Inc. added, “We believe that by targeting cannabinoid receptors we open up a range of therapeutic pathways unaddressed by today’s medications. Whether alone or in combination, we believe such medications can provide great value to patients, not least to those suffering the blight of undertreated pain.  By combining our capabilities and focusing our resources to generate the right drug for the right patient, the Tetra/Altus joint venture overcomes many of the hurdles that have dogged cannabinoid medicine commercialization in the past. We greatly look forward to working with the Tetra team and to bringing these products to the market.

About Altus Formulation Inc.
Altus Formulation is a Quebec based drug formulation and development company using its proprietary and patent protected drug delivery technologies to generate novel, differentiated and cost-effective new products for its partners and their patients. With a focus on Safer to Use™ formulations, Altus’ technologies include Intellitab™ abuse deterrent technology, Flexitab™ breakable extended release tablets and SmartCelle™ technologies for delivery of low solubility large and small molecules.

For more information, please visit www.altusformulation.com

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Health Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Vertical Exploration $VERT.ca Engages with AGRINOVA for Wollastonite Research and Development

Posted by AGORACOM at 8:30 AM on Monday, April 29th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564648/hub/vertical.png
  • AGRINOVA is a highly-regarded Center for Research and Innovation in Agriculture in Quebec
  • Contracted to optimize the potential agricultural uses of wollastonite through innovstion of production methods for farmers and agricultural companies located in Quebec.
  • The research and development program being conducted by AGRINOVA consists of three phases
  • 3 Phases are: product characterization and uses of wollastonite, a market study and the implementation of an applied research program being conducted on the farmlands of the Saguenay Region in Quebec.

VANCOUVER, BC / ACCESSWIRE / April 29, 2019 / VERTICAL EXPLORATION INC. (TSX-V: VERT) (“Vertical” or “the Company”) is pleased to update shareholders that it has engaged with AGRINOVA over the past year to conduct research and testing of Vertical’s St-Onge wollastonite on a range of important agricultural end uses. AGRINOVA, which is a highly-regarded Center for Research and Innovation in Agriculture in Quebec, has been contracted to manage all aspects of a comprehensive research and development program in an effort to optimize the potential agricultural uses of wollastonite and in turn help improve production methods for farmers and agricultural companies located in Quebec.

The research and development program being conducted by AGRINOVA consists of three phases, including product characterization and uses of wollastonite, a market study and the implementation of an applied research program being conducted on the farmlands of the Saguenay Region in Quebec.

The agronomic characterization and verification of wollastonite’s uses in agriculture is particularly important to Vertical, as results generated from this ongoing research program will support the Company’s plans to market its wollastonite to a range of agricultural customers. The applied research and development work being conducted by AGRINOVA will also directly support the certification of Vertical’s St-Onge wollastonite by the Bureau de normalisation du Québec (BNQ), an organization accredited by the Standards Council of Canada (SCC), which is a necessary first step for Vertical to take before moving forward with initial sales efforts for its St-Onge wollastonite in Quebec.

Initial results from the three phase program are anticipated to be released within the next few weeks.

ABOUT AGRINOVA

AGRINOVA (www.agrinova.qc.ca), the Center for Research and Innovation in Agriculture, is a Technology Access Centre located in Alma, Quebec that provides technical help and services to farmers and agricultural companies throughout the province in order to help them access new technologies and assist them with the adoption of innovative new technologies and practices. AGRINOVA’s technology support focuses primarily on consumer concerns (milk quality); reducing greenhouse gas (GHG) emissions; organic or natural products; comfort and well-being of animals; digital adoption; and the economic efficiency of companies.

ABOUT VERTICAL EXPLORATION

Vertical Exploration’s mission is to identify, acquire, and advance high potential mining prospects located in North America for the benefit of its stakeholders. The Company’s St-Onge Wollastonite property is located in the Lac-Saint-Jean area in the Province of Quebec.

ON BEHALF OF THE BOARD
Peter P. Swistak, President/CEO

FOR FURTHER INFORMATION PLEASE CONTACT: Telephone: 1-604-683-3995 Toll Free: 1-888-945-4770